GP28 zT2
Alternative Names: GP28-zT2Latest Information Update: 07 Feb 2024
At a glance
- Originator Wellington Zhaotai Therapies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Liver cancer
Most Recent Events
- 07 Feb 2024 GP28 zT2 is available for licensing as of 07 Feb 2024. https://www.wellingtonzhaotai.com/business-development
- 07 Feb 2024 Phase-I clinical trials in Liver cancer in Unknown location (Parenteral) (Wellington Zhaotai Therapies pipeline, February 2024)
- 05 Feb 2024 Wellington Zhaotai Therapies has patent protection for CAR T-cell construct with unique, co-stimulatory domain (Wellington Zhaotai Therapies pipeline, February 2024)